Vietnam to overtake Indonesia in per capita GDP in 2026: IMF
We haven't written up this one. Nikkei Asia has the full story — the link below goes straight to it.
More in Finance & Markets
Before the Midterms, a Debate Over Where Data Centers Belong and Who Pays for Their Power
News Provided by USA News Group on behalf of Host Digital Inc. NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) — USA News Group News Commentary – With the November 3 midterm elections days away, data centers…
Budget winners and losers : Some get a £100 energy handout... but landlords and savers are hammered
Middle income families could end up footing the bill for Healey's handouts to those on lower incomes... but it's good news for people who like gherkins.
Fed rate hold offers little comfort to Indian markets as two members seek a hike
Analysts say the split vote keeps the risk of tighter US monetary policy alive, with foreign fund flows, rupee and Nifty volatility in focus
Is Ares Capital Corp a Buy After Its Latest Earnings Report?
Ares Capital's latest earnings highlighted some concerns about its ability to cover its high-yielding dividend.
- Ares Capital's Q3 earnings per share fell to $0.46, below its $0.48 dividend.
- CFO Scott Lem says $1.37/share taxable income can sustain dividend.
- $2.6B acquisition of MFIC expected to boost future dividends and EPS.
Is Alphabet a Stock to Avoid or a Once-in-a-Decade Buy on the Dip?
The stock fell after the company’s latest earnings report.
- Alphabet shares fell 20% post-earnings report
- AI-driven growth boosts Google Search and advertising revenue
- Potential "once-in-a-decade buy" on current dip
Genmab's stock rises on cancer data, while Iovance, Coherus tumble
Cancer trial news drove a number of stock moves in both directions over the past 24 hours. Here's a summary of key results and their impact: Genmab shares rise on head and neck cancer data: ...